<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="condition" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">4. Discussion</segment>
<segment id="2" parent="1003" relname="span">Recognizing patients with monogenic AIDs is difficult</segment>
<segment id="3" parent="2" relname="cause">because their clinical spectrum may range from very mild inflammatory episodes to severe chronic disease .</segment>
<segment id="4" parent="1002" relname="span">Moreover , the disease features significantly overlap .</segment>
<segment id="5" parent="1006" relname="span">Our targeted NGS approach resulted in genetic confirmation in a relatively small proportion</segment>
<segment id="6" parent="5" relname="restatement">( 7 % )</segment>
<segment id="7" parent="1005" relname="same_unit">of patients .</segment>
<segment id="8" parent="1008" relname="span">This finding is consistent with two 2019 reports by Karacan et al. and Papa et al. ,</segment>
<segment id="9" parent="1009" relname="span">who used recent guidelines for the definition of positive diagnosis</segment>
<segment id="10" parent="9" relname="elaboration">as we did .</segment>
<segment id="11" parent="1012" relname="span">Three previous studies</segment>
<segment id="12" parent="1013" relname="same_unit">using a broader definition</segment>
<segment id="13" parent="1013" relname="same_unit">claimed 19 % , 20 % , and 22 % diagnostic yield .</segment>
<segment id="14" parent="1016" relname="span">In those reports , for example , frequent variants , such as p. ( Glu148Gln )</segment>
<segment id="15" parent="14" relname="elaboration">( MEFV ) ,</segment>
<segment id="16" parent="1018" relname="span">p. ( Arg121Gln )</segment>
<segment id="17" parent="1019" relname="contrast">( TNFRSF1A ) ,</segment>
<segment id="18" parent="1019" relname="contrast">or p. ( Val198Met )</segment>
<segment id="19" parent="1018" relname="elaboration">( NLRP3 ) ,</segment>
<segment id="20" parent="1020" relname="same_unit">and all known susceptibility factors for inflammation</segment>
<segment id="21" parent="1020" relname="same_unit">were considered consistent with the diagnosis .</segment>
<segment id="22" parent="1001" relname="joint">Moreover , our definition was more stringent than these four previous studies</segment>
<segment id="23" parent="1024" relname="attribution">because we considered</segment>
<segment id="24" parent="1024" relname="span">that we could not conclude on the diagnosis</segment>
<segment id="25" parent="24" relname="circumstance">when the parent â€™s DNA was lacking segregation analyses of heterozygous rare VOUS .</segment>
<segment id="26" parent="1026" relname="span">The low performance of the AIDs panel might also be explained by our study design</segment>
<segment id="27" parent="1027" relname="span">that did not include most of the patients with features of FMF , MKD , and DADA2</segment>
<segment id="28" parent="27" relname="cause">because they were screened by Sanger sequencing .</segment>
<segment id="29" parent="1029" relname="preparation">Still , the genes MEFV , MVK , and ADA2 remained among the four most frequently involved in the conclusive diagnoses of our study .</segment>
<segment id="30" parent="1031" relname="span">This observation possibly stems from a better detection by NGS of the new molecular mechanisms</segment>
<segment id="31" parent="1032" relname="span">involved in AIDs</segment>
<segment id="32" parent="31" relname="restatement">( mosaicism , CNVs )</segment>
<segment id="33" parent="1033" relname="span">and better information on these three diseases</segment>
<segment id="34" parent="33" relname="cause">because they are among the best-described AIDs .</segment>
<segment id="35" parent="1035" relname="span">In addition , FMF is now recognized as a disease</segment>
<segment id="36" parent="1036" relname="span">caused by gain-of-function variants with a dosage effect</segment>
<segment id="37" parent="36" relname="antithesis">rather than a purely recessive condition .</segment>
<segment id="38" parent="1038" relname="span">For one-third of the patients with one heterozygous pathogenic variant in a recessive condition , the gene was MEFV .</segment>
<segment id="39" parent="40" relname="condition">If we had included heterozygous carriers of a MEFV pathogenic variant ,</segment>
<segment id="40" parent="1039" relname="span">the genetic diagnosis yield would have improved up to 10 % (</segment>
<segment id="41" parent="1041" relname="preparation">Figure 2</segment>
<segment id="42" parent="1041" relname="joint">) .</segment>
<segment id="43" parent="1043" relname="span">In an attempt</segment>
<segment id="44" parent="1045" relname="span">to find a cause</segment>
<segment id="45" parent="44" relname="elaboration">that could explain the low rate of genetic confirmation</segment>
<segment id="46" parent="1046" relname="span">using panels in the patients</segment>
<segment id="47" parent="46" relname="elaboration">referred to us ,</segment>
<segment id="48" parent="49" relname="attribution">we wondered</segment>
<segment id="49" parent="1048" relname="span">whether validation of the request by a specialized reference center could improve this performance .</segment>
<segment id="50" parent="1050" relname="preparation">The success of the NGS approach was suggested to rely on its use in the context of a highly specialized clinical service for patients with AIDs .</segment>
<segment id="51" parent="1051" relname="span">National reference centers and networks cover all the expertise</segment>
<segment id="52" parent="51" relname="elaboration">necessary for patient care and operational management and efficiency .</segment>
<segment id="53" parent="1053" relname="preparation">We established a pre-requisite for a systematic evaluation of undifferentiated AIDs patients by clinicians from reference centers .</segment>
<segment id="54" parent="1055" relname="attribution">It is possible</segment>
<segment id="55" parent="1055" relname="span">that many doctors from non-reference centers could not find the time</segment>
<segment id="56" parent="55" relname="purpose">to present their patients to MSM .</segment>
<segment id="57" parent="1057" relname="preparation">This certainly accounts for the decrease in the proportion of patients referred by the non-reference centers .</segment>
<segment id="58" parent="1059" relname="attribution">However , our study showed</segment>
<segment id="59" parent="1059" relname="span">that this strategy resulted in a better clinical filter</segment>
<segment id="60" parent="1060" relname="joint">for ordering genetic tests</segment>
<segment id="61" parent="1060" relname="joint">and almost doubled the performance of our NGS strategy .</segment>
<segment id="62" parent="1062" relname="span">Also , our reference center recently offered a diagnostic checklist</segment>
<segment id="63" parent="1063" relname="span">to guide practitioners</segment>
<segment id="64" parent="1064" relname="span">who may suspect an AID</segment>
<segment id="65" parent="64" relname="purpose">for ordering genetic tests .</segment>
<segment id="66" parent="1066" relname="span">In our patients with a conclusive diagnosis of AID ,</segment>
<segment id="67" parent="1067" relname="span">the main features</segment>
<segment id="68" parent="67" relname="elaboration">identified were mucocutaneous , articular , and gastro-intestinal .</segment>
<segment id="69" parent="1068" relname="span">This result reflects daily practice</segment>
<segment id="70" parent="1070" relname="span">because the cutaneous/mucosal , digestive tract , and musculoskeletal systems are the three most common systems</segment>
<segment id="71" parent="70" relname="elaboration">involved in AIDs .</segment>
<segment id="72" parent="1071" relname="joint">We cannot rule out a relative underestimation of the potential of NGS panels for AIDs in general .</segment>
<segment id="73" parent="1072" relname="contrast">Indeed , because of our study design , some of the patients or their relatives were not available for NGS or segregation analysis .</segment>
<segment id="74" parent="1074" relname="contrast">However , our aim was not to evaluate the exact performance of NGS</segment>
<segment id="75" parent="1075" relname="span">but to find ways</segment>
<segment id="76" parent="75" relname="purpose">to improve it .</segment>
<segment id="77" parent="1078" relname="span">In addition to the successful clinical option</segment>
<segment id="78" parent="77" relname="elaboration">we demonstrated here ,</segment>
<segment id="79" parent="1080" relname="span">it is easy to predict the upcoming discovery of new genes or molecular mechanisms</segment>
<segment id="80" parent="79" relname="elaboration">involved in AIDs</segment>
<segment id="81" parent="1080" relname="elaboration">that will continue to revolutionize our routine genetic diagnosis .</segment>
<segment id="82" parent="1081" relname="joint">Recent inputs of the literature advocate closer interactions between clinicians and geneticists in the era of whole-genome sequencing .</segment>
<segment id="83" parent="1083" relname="span">Among them are the identification of genetic modifiers ,</segment>
<segment id="84" parent="1085" relname="span">affecting the penetrance of homozygous pathogenic MVK : p.</segment>
<segment id="85" parent="84" relname="elaboration">( Val377Ile ) variant ;</segment>
<segment id="86" parent="1086" relname="span">the lack of detection of pathogenic variants in patients with a clear given phenotype , such as pathogenic canonical splice site variants</segment>
<segment id="87" parent="1087" relname="span">not covered by Sanger and panel approaches</segment>
<segment id="88" parent="1089" relname="joint">( e.g. , ADA2 : c. -47+2T&gt;C ) ;</segment>
<segment id="89" parent="1089" relname="joint">or large chromosomal rearrangements ,</segment>
<segment id="90" parent="1089" relname="elaboration">encompassing several genes in patients with complex phenotypes .</segment>
<segment id="91" parent="1090" relname="joint">In those circumstances , an MSM could help find the best appropriate strategy in accordance with the patient â€™s phenotype .</segment>
<segment id="92" parent="1092" relname="span">The role of the reference centers is to determine whether or not the clinical/anamnesis/genealogical tree is compatible with a known AID .</segment>
<segment id="93" parent="1095" relname="condition">If compatibility does not seem to be the case ,</segment>
<segment id="94" parent="1095" relname="span">the role is to evaluate the potential added value</segment>
<segment id="95" parent="94" relname="purpose">to perform the NGS .</segment>
<segment id="96" parent="1097" relname="condition">If this value appears to be low ,</segment>
<segment id="97" parent="98" relname="attribution">the reference center recommends</segment>
<segment id="98" parent="1097" relname="span">that no NGS be conducted in discussion with geneticists .</segment>
<segment id="99" parent="1098" relname="span">Thus , this discussion decreases the number of individuals</segment>
<segment id="100" parent="99" relname="elaboration">whose phenotype is not typically enough .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="joint"/>
<group id="1003" type="span" parent="4" relname="background"/>
<group id="1005" type="multinuc" parent="1001" relname="joint"/>
<group id="1006" type="span" parent="1005" relname="same_unit"/>
<group id="1008" type="span" parent="1001" relname="joint"/>
<group id="1009" type="span" parent="8" relname="elaboration"/>
<group id="1011" type="span" parent="1001" relname="joint"/>
<group id="1012" type="span" parent="1011" relname="span"/>
<group id="1013" type="multinuc" parent="11" relname="means"/>
<group id="1014" type="multinuc" parent="1012" relname="elaboration"/>
<group id="1015" type="multinuc" parent="1014" relname="same_unit"/>
<group id="1016" type="span" parent="1015" relname="same_unit"/>
<group id="1017" type="span" parent="1015" relname="same_unit"/>
<group id="1018" type="span" parent="1017" relname="span"/>
<group id="1019" type="multinuc" parent="16" relname="restatement"/>
<group id="1020" type="multinuc" parent="1014" relname="same_unit"/>
<group id="1023" type="span" parent="1001" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="span"/>
<group id="1026" type="span" parent="1001" relname="joint"/>
<group id="1027" type="span" parent="26" relname="elaboration"/>
<group id="1028" type="span" parent="1001" relname="joint"/>
<group id="1029" type="multinuc" parent="1028" relname="span"/>
<group id="1031" type="span" parent="1029" relname="joint"/>
<group id="1032" type="span" parent="30" relname="elaboration"/>
<group id="1033" type="span" parent="1029" relname="joint"/>
<group id="1035" type="span" parent="1029" relname="joint"/>
<group id="1036" type="span" parent="35" relname="elaboration"/>
<group id="1037" type="span" parent="1029" relname="joint"/>
<group id="1038" type="span" parent="1040" relname="preparation"/>
<group id="1039" type="span" parent="38" relname="elaboration"/>
<group id="1040" type="span" parent="1037" relname="span"/>
<group id="1041" type="multinuc" parent="1040" relname="span"/>
<group id="1043" type="span" parent="1041" relname="joint"/>
<group id="1044" type="span" parent="43" relname="purpose"/>
<group id="1045" type="span" parent="1044" relname="span"/>
<group id="1046" type="span" parent="1045" relname="means"/>
<group id="1047" type="span" parent="1041" relname="joint"/>
<group id="1048" type="span" parent="1049" relname="preparation"/>
<group id="1049" type="span" parent="1047" relname="span"/>
<group id="1050" type="span" parent="1049" relname="span"/>
<group id="1051" type="span" parent="1052" relname="preparation"/>
<group id="1052" type="span" parent="1050" relname="span"/>
<group id="1053" type="span" parent="1052" relname="span"/>
<group id="1054" type="span" parent="1056" relname="preparation"/>
<group id="1055" type="span" parent="1054" relname="span"/>
<group id="1056" type="span" parent="1053" relname="span"/>
<group id="1057" type="multinuc" parent="1056" relname="span"/>
<group id="1058" type="span" parent="1057" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="span"/>
<group id="1060" type="multinuc" parent="59" relname="purpose"/>
<group id="1062" type="span" parent="1057" relname="joint"/>
<group id="1063" type="span" parent="62" relname="purpose"/>
<group id="1064" type="span" parent="63" relname="elaboration"/>
<group id="1066" type="span" parent="1057" relname="joint"/>
<group id="1067" type="span" parent="66" relname="elaboration"/>
<group id="1068" type="span" parent="1057" relname="joint"/>
<group id="1069" type="multinuc" parent="69" relname="cause"/>
<group id="1070" type="span" parent="1069" relname="joint"/>
<group id="1071" type="multinuc" parent="1069" relname="joint"/>
<group id="1072" type="multinuc" parent="1071" relname="joint"/>
<group id="1073" type="multinuc" parent="1072" relname="contrast"/>
<group id="1074" type="multinuc" parent="1073" relname="joint"/>
<group id="1075" type="span" parent="1074" relname="contrast"/>
<group id="1076" type="multinuc" parent="1073" relname="joint"/>
<group id="1077" type="multinuc" parent="1076" relname="joint"/>
<group id="1078" type="span" parent="1077" relname="same_unit"/>
<group id="1079" type="span" parent="1077" relname="same_unit"/>
<group id="1080" type="span" parent="1079" relname="span"/>
<group id="1081" type="multinuc" parent="1076" relname="joint"/>
<group id="1082" type="multinuc" parent="1081" relname="joint"/>
<group id="1083" type="span" parent="1082" relname="joint"/>
<group id="1084" type="span" parent="83" relname="elaboration"/>
<group id="1085" type="span" parent="1084" relname="span"/>
<group id="1086" type="span" parent="1085" relname="elaboration"/>
<group id="1087" type="span" parent="86" relname="elaboration"/>
<group id="1088" type="span" parent="87" relname="elaboration"/>
<group id="1089" type="multinuc" parent="1088" relname="span"/>
<group id="1090" type="multinuc" parent="1082" relname="joint"/>
<group id="1091" type="multinuc" parent="1090" relname="joint"/>
<group id="1092" type="span" parent="1091" relname="joint"/>
<group id="1093" type="span" parent="92" relname="elaboration"/>
<group id="1094" type="span" parent="1093" relname="span"/>
<group id="1095" type="span" parent="1094" relname="span"/>
<group id="1096" type="span" parent="1094" relname="elaboration"/>
<group id="1097" type="span" parent="1096" relname="span"/>
<group id="1098" type="span" parent="1091" relname="joint"/>
	</body>
</rst>
